Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment, and Acute Lymphoblastic Leukemia research.
Targeting menin in T-lineage acute lymphoblastic leukemia.
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial
Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms
Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study
Data from Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia
Supplementary Table 1 from Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia
Supplementary figures 1-9 from Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.
Supplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplementary Raw Data Tables from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplementary Raw Data Tables from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Data from Dual targeting of apoptotic and signaling pathways in T-lineage acute lymphoblastic leukemia
Supplementary Table 1 from Dual targeting of apoptotic and signaling pathways in T-lineage acute lymphoblastic leukemia
Supplementary figures 1-9 from Dual targeting of apoptotic and signaling pathways in T-lineage acute lymphoblastic leukemia
Supplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplementary Tables 1-11 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplementary figures 1-9 from Dual targeting of apoptotic and signaling pathways in T-lineage acute lymphoblastic leukemia
Supplementary Table 1 from Dual targeting of apoptotic and signaling pathways in T-lineage acute lymphoblastic leukemia
Data from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
Supplementary Table 1 from Dual targeting of apoptotic and signaling pathways in T-lineage acute lymphoblastic leukemia
Supplementary Table 1 from Dual targeting of apoptotic and signaling pathways in T-lineage acute lymphoblastic leukemia